To be able to achieve our access goal, it is important for us to know how we are performing today. In 2020 we strengthened our assessment of access performance for our key medicines. This analysis started with an initial consideration of 14 countries (Belgium, China, Denmark, Finland, France, Germany, Italy, Japan, Netherlands, Norway, Spain, Sweden, the United Kingdom, and the United States [Medicaid, Medicare, and Commercial insurance]) for four products (Briviact®, Cimzia®, Evenity®, and Vimpat®).
With the baseline established for these countries and reported in our performance section, we are working towards increasing access for patients who need our medicines. We are committed to delivering access to all these patients by 2030 and as such our performance will be assessed and disclosed every year and compared to our prior year baseline to make sure that we are on track to deliver on our commitments.
In support of our access commitment, in the U.S. affordability information for UCB’s products is available to patients and all stakeholders on our website. Additionally, this year we expanded our existing Patient Assistance Program (PAP) to help eligible patients impacted by COVID-19 to ensure uninterrupted access to their medicines at no cost. This change helps patients experiencing difficulty affording UCB medicines due to job loss, furlough, or loss of insurance coverage. We are also participating in several additional programs aimed at helping those impacted by the pandemic stay on needed therapies.
In 2020, our U.S. net (after discounts and rebates) price change remained in line with inflation at an average of 0.4% across the U.S. product portfolio (list price change averaged 5%). At a product level, the largest single percentage change was a 7% list price increase and a 0.5% net price change from 2019 to 2020.